Biomolecules & Therapeutics
Strategies for Manipulating T Cells in Cancer Immunotherapy
Hyang-Mi Lee
College of Pharmacy, Dongduk Women’s University, Seoul 02748, Republic of Korea
Tel: +82-2-940-4524, Fax: +82-2-940-4159
Received: December 2, 2021; Revised: January 13, 2022; Accepted: February 8, 2022; Published online: March 10, 2022.
© The Korean Society of Applied Pharmacology. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
T cells are attractive targets for the development of immunotherapy to treat cancer due to their biological features, capacity of cytotoxicity, and antigen-specific binding of receptors. Novel strategies that can modulate T cell functions or receptor reactivity provide effective therapies, including checkpoint inhibitor, bispecific antibody, and adoptive transfer of T cells transduced with tumor antigen-specific receptors. T cell-based therapies have presented successful pre-clinical/clinical outcomes despite their common immune-related adverse effects. Ongoing studies will allow us to advance current T cell therapies and develop innovative personalized T cell therapies. This review summarizes immunotherapeutic approaches with a focus on T cells. Anti-cancer T cell therapies are also discussed regarding their biological perspectives, efficacy, toxicity, challenges, and opportunities.
Keywords: Cancer immunotherapy, Checkpoint inhibitor, Bispecific antibody, Adoptive T cell transfer, Tumor-specific T cells

This Article

Cited By Articles
  • CrossRef (0)